Gilead Sciences Inc. (GILD) is set to report fourth-quarter 2023 results on Feb 6, after market close. The company has a mixed track record, with earnings beating estimates in two of the last four quarters and missing in the remaining two, the average negative surprise being 0.24%. In the last reported quarter, the company posted an earnings surprise of 19.9%. Factors to Note Revenues in the fourth quarter have likely been boosted by growth in oncology and HIV franchise sales. However, a decline in Veklury ...